UPS Healthcare is opening the first-of-its-kind healthcare logistics facility in Dublin today to meet growing demand for the pharma and medical device industries in Ireland.
UPS said the €12m facility covers nearly 6,000 m² and has created an initial 30 new jobs.
Fitted with specialised technology, the new facility provides in-demand storage and inbound and outbound transportation for a range of pharmaceutical and health tech products.
UPS said its new facility will house small package, freight forwarding and logistics and distribution capabilities and will connect customers from all industries to an integrated global network that is adaptable and resilient to their needs.
UPS said that 80% of pharma products in Europe already require temperature-controlled transportation.
"The latest biologics and specialty pharmaceuticals require precision, temperature-controlled logistics to get patient-critical products where they need to be, on time and at the right temperature," it added.
UPS noted that the country's pharma market is now more reliant on advanced temperature-controlled logistics to help meet its needs. The industry already accounts for nearly 50% of the country's exports and the market is expected to hit annual growth of 6.17% from this year up to 2028.
Cathy O’Brien, Vice President for International Sales at UPS Healthcare, said the new investment marks the company's commitment to supporting Ireland's pharmaceutical and medical device industries.
"We're the only provider who can take our customers' treatments from clinical trial right to the patient, turning logistics into a competitive advantage, one that will only help grow Ireland’s position as a central hub for the pharma industry," she said.
Michael Lohan, CEO of IDA Ireland, said the new UPS Healthcare facility will support the country's thriving pharmaceutical and medical technology sector.
"With this investment of €12m, UPS Healthcare is showing its commitment to innovation but also reinforcing Ireland’s reputation as a leading hub for excellence across the life sciences sector," he added.
